期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米为主化疗方案治疗多发性骨髓瘤12例疗效分析 被引量：1

原文传递
导出
摘要 目的:分析硼替佐米为主化疗方案治疗初始与复发难治多发性骨髓瘤(MM)患者的临床疗效和不良反应。方法:12例患者采用下列3种联合化疗中的一种,VD方案4例【硼替佐米1-1.3mg/m2d1.d4.d8.d11天快速静脉注射+地塞米松注射液40mgd1-4天、d9-12天静注滴注、第17-20天静注滴注(单周),第1-4天静注滴注(双周)】,3周为一疗程。VDT方案6例(硼替佐米1-1.3mg/m2第1.4.8和11天快速静脉注射+地塞米松20mgd1d2d4d5d8d9d11d12+沙利度胺片100-200mgd1-d21天),3周为一疗程。PAD方案2例(硼替佐米硼替佐米1-1.3mg/m2d1.d4.d8.d11天快速静脉注射+多柔比星10mg/d d1-d4天静脉滴注+地塞米松40mg d1-d4天静脉滴注),3周为一疗程。缓解后维持沙利度胺片100-200mg一日一次口服。结果:12例患者中随访(3-18月),CR/NCR 3例,VGPR 5例,PR 2例,MR 0例,NC 1例,PD 1例,有效率(RR=CR/NCR8+VGPR2+PR+MR/12)83.3%。有效的10例患者中,2例在治疗1疗程后即达CR/NCR,3例在治疗2疗程后即达CR/NCR,3例在治疗4疗程后即达CR/NCR,2例在治疗4疗程后即达CR/NCR。12例患者的主要不良反应有胃肠道症状(7/12),周围神经病变5/12)、白细胞减少(3/12),血小板减少(2/12),感染(3/12),1例患者出现血糖增高(1/12),1例患者发生心律失常。结论:硼替佐米联合地塞米松与沙利度胺治疗初始MM起效快,总体反应率及完全缓解率高;该方案用于复发、难治性MM亦有较高治疗反应率,但疗效逊于初始患者。不良反应程度轻微,可控制和预测,总体耐受性良好。
作者 杨永健 钱震
机构地区 新疆兵团四师医院 江苏镇江第一人民医院
出处 《兵团医学》 2013年第4期27-29,共3页 Journal of BingTuan Medicine
关键词 多发性骨髓瘤 不良反应 地塞米松 化疗方案 沙利度胺 有效率 周围神经病变 静脉注射 临床治疗 患者
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1Wu Ka Lung,van Wieringen Wessel,Vellenga Edo,Zweegman Sonja,Lokhorst Henk M,Sonneveld Pieter.Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica . 2005
  • 2Mateos MV,Hernandez JM,Hernandez MT,et al.Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood . 2006
  • 3Richardson Paul G,Barlogie Bart,Berenson James,Singhal Seema,Jagannath Sundar,Irwin David,Rajkumar S Vincent,Srkalovic Gordan,Alsina Melissa,Alexanian Raymond,Siegel David,Orlowski Robert Z,Kuter David,Limentani Steven A,Lee Stephanie,Hides.A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Quarterly . 2003
  • 4SundarJagannath,Brian G. M.Durie,JeffreyWolf,ElberCamacho,DavidIrwin,JoseLutzky,MartiMcKinley,EliGabayan,AmitabhaMazumder,DavidSchenkein,JohnCrowley.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J]. British Journal of Haematology . 2005 (6)
  • 5Asher A. Chanan-Khan,Jonathan L. Kaufman,Jayesh Mehta,Paul G. Richardson,Kena C. Miller,Sagar Lonial,Nikhil C. Munshi,Robert Schlossman,Joseph Tariman,Seema Singh.Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood . 2007
  • 6Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood . 2003
  • 7钟玉萍,陈世伦,李新,胡影,张佳佳.硼替佐米为主的化疗方案治疗60例多发性骨髓瘤患者的临床分析[J].中国实验血液学杂志,2009,17(1):214-217. 被引量：24
  • 8MartinKropff,GuidoBisping,ElkeSchuck,PeterLiebisch,NicolaLang,MarkusHentrich,TobiasDechow,NicolausKr?ger,HansSalwender,BerndMetzner,OrhanSezer,MonikaEngelhardt,Hans‐HeinrichWolf,HermannEinsele,SarahVolpert,AchimHeinecke,Wolfgang E.Berdel,JoachimKienast.Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma[J]. British Journal of Haematology . 2007 (3)
  • 9中国多发性骨髓瘤诊治指南[J].中华内科杂志,2008,47(10):869-872. 被引量：88

二级参考文献11

  • 1邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志：临床前沿版,2006,26(6):886-888. 被引量：52
  • 2黄文荣,李荣,靖域,张翼鷟,吴晓雄,高春记,薄剑,于力,王全顺,达万明.蛋白酶体抑制剂硼酸盐二肽治疗难治性多发性骨髓瘤[J].中国实验血液学杂志,2006,14(6):1146-1150. 被引量：3
  • 3Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood, 2004 ; 103:20 - 32.
  • 4Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med, 1997 ;336 : 1657 - 1664.
  • 5UK Myeloma Forum. Britsh Sommittee for Standards in Huematology. Diagnosis and management of multiple myeloma. Br J Haematol, 2001 ; 115 ;522 - 540.
  • 6Blade J, Samson D, Reece D, et al. Criteria for evaluating disease reponse and progression in patients with multiple myeloma treated by high-dose tgerapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol,1998 ;102:1115 - 1123.
  • 7Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 2003 ; 101:2377 - 2380.
  • 8Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res,2003 ;9 : 1136 - 1144.
  • 9Kropff MH, Bispinga G, Wenning D, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res, 2005 ;29:587 -590.
  • 10钟玉萍,陈世伦,李新,张佳佳,安娜.硼替佐米联合其他药物治疗30例多发性骨髓瘤患者的临床观察[J].中华内科杂志,2008,47(2):137-138. 被引量：7

共引文献110

同被引文献19

  • 1陈兵.蛋白酶体抑制剂-硼替佐米在侵袭性恶性淋巴瘤治疗中的应用[J].药物与临床研究,2010,2:104-106.
  • 2Moreau P,Attal M,Facon T.Frontline therapy of multiple myeloma[J].Blood,2015,125(20):3076-3084.
  • 3Cancer Therapy Evaluation Program.Common terminology criteria for adverse events v3.0(CTCAE),DCTD,NCI,NIH,DHHS[S].2003.
  • 4Tricot G,Jagannath S,Vesole D H,et al.Hemalopoietic stem cell transplants for multiple myeloma[J].Leuk Lymphoma,1996,22(1-2):25-36.
  • 5Hideshima T,Richardson P,Chauhan D,et al.The proteasome inhibitor PS-341 nihibits growth,niduces apoptosis,and overcomes drug resistance in human multiple myeloma cells[J].Cancer Res,2001,61(7):3071-3076.
  • 6Jagannath S,Durie B G,Wolf J,et al.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma[J].Br J Haematol,2005,129(6):776-783.
  • 7Harousseau J L,Attal M,Leleu X,et al.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:results of an IFM phaseⅡstudy[J].Haematologica,2006,91(11):1498-1505.
  • 8Harousseau J L,Attal M,Avet-Loiseau H,et al.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma:results of the IFM 2005-01 phaseⅢtrial[J].J Clin Oncol,2010,28(30):4621-4629.
  • 9Cavo M,Tacchetti P,Patriarca F,et al.Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomidedexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma[J].Blood,2008,112(11):65.
  • 10钟玉萍,陈世伦,李新,张佳佳,安娜.硼替佐米联合其他药物治疗30例多发性骨髓瘤患者的临床观察[J].中华内科杂志,2008,47(2):137-138. 被引量：7

引证文献1

二级引证文献8

兵团医学
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部